Claims
- 1. A pharmaceutical composition comprising venlafaxine hydrochloride and sodium carboxymethyl cellulose.
- 2. The pharmaceutical composition according to claim 1, wherein said venlafaxine hydrochloride is racemic venlafaxine hydrochloride.
- 3. The pharmaceutical composition according to claim 1, wherein said venlafaxine hydrochloride is (+)-venlafaxine hydrochloride or (−)-venlafaxine hydrochloride.
- 4. The pharmaceutical composition according to claim 1, wherein said venlafaxine hydrochloride and said sodium carboxymethyl cellulose are present in a weight ratio of 0.8-1.2:1, respectively.
- 5. The pharmaceutical composition according to claim 4, wherein said weight ratio is about 1:1.
- 6. The pharmaceutical composition according to claim 1, wherein said composition is in the form of a tablet containing a pharmaceutically effective amount of venlafaxine hydrochloride.
- 7. The pharmaceutical composition according to claim 6, wherein said tablet contains 10%-50% of said venlafaxine hydrochloride and 30% to 75% of said sodium carboxyrnethyl cellulose.
- 8. The pharmaceutical composition according to claim 7, wherein said venlafaxine hydrochloride and said sodium carboxymethyl cellulose are present in said tablet in a weight ratio of about 1:1.
- 9. The pharmaceutical composition according to claim 6, wherein said tablet contains 30 to 300 mg of venlafaxine as said venlafaxine hydrochloride.
- 10. The pharmaceutical composition according to claim 6, wherein said tablet further comprises hydroxypropyl methylcellulose, microcrystalline cellulose, or a combination thereof.
- 11. The pharmaceutical composition according to claim 6, which further comprises a coating.
- 12. The pharmaceutical composition according to claim 6, wherein said tablet has a dissolution profile wherein no more than 30% of said venlafaxine hydrochloride is released during the first two hours in a USP Apparatus 1 (basket) at 100 rpm in purified water at 37° C.
- 13. The pharmaceutical composition according to claim 12, wherein said tablet dissolution profile meets the following criterion:
- 14. A method for treating a venlafaxine-treatable disease or condition, which comprises administering to a patient in need thereof an effective amount of the pharmaceutical position according to claim 1.
- 15. The method according to claim 14, wherein said venlafaxine-treatable disease or condition is depression.
- 16. The method according to claim 15, wherein said composition is administered once daily.
- 17. The method according to claim 16, wherein said pharmaceutical composition is administered orally in the form of one or two tablets once daily.
Parent Case Info
[0001] This application claims the benefit of priority under 35 U.S.C. §119 from prior U.S. provisional application serial No. 60/367,735, filed Mar. 28, 2002, the entire contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60367735 |
Mar 2002 |
US |